| 87.035 1.765 (2.07%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 108.58 | 1-year : | 121.84 |
| Resists | First : | 92.96 | Second : | 104.31 |
| Pivot price | 92.37 |
|||
| Supports | First : | 74.58 | Second : | 62.05 |
| MAs | MA(5) : | 88.32 |
MA(20) : | 90.03  |
| MA(100) : | 73.17 |
MA(250) : | 60.77 |
|
| MACD | MACD : | 1.5 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 34.4 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 104.31 | Low : | 31.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TEM ] has closed above bottom band by 20.5%. Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.96 - 89.46 | 89.46 - 89.91 |
| Low: | 82.79 - 83.42 | 83.42 - 84.01 |
| Close: | 86.1 - 87.04 | 87.04 - 87.89 |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Fri, 24 Oct 2025
International Assets Investment Management LLC Buys Shares of 3,362 Tempus AI, Inc. $TEM - MarketBeat
Thu, 23 Oct 2025
3,515 Shares in Tempus AI, Inc. $TEM Purchased by Atria Wealth Solutions Inc. - MarketBeat
Wed, 22 Oct 2025
BTIG Maintains Tempus AI (TEM) Buy Recommendation - Nasdaq
Tue, 21 Oct 2025
Tempus to Report Third Quarter 2025 Financial Results on November 4 - Business Wire
Tue, 21 Oct 2025
Tempus AI (TEM): Exploring Valuation After a 43% Three-Month Rally - Yahoo
Mon, 20 Oct 2025
Tempus AI Shares Are Trading Higher Monday: What's Going On? - Tempus AI (NASDAQ:TEM) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 169 (M) |
| Held by Insiders | 1.0474e+008 (%) |
| Held by Institutions | 41.8 (%) |
| Shares Short | 24,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.741e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -11.6 % |
| Qtrly Rev. Growth | 9.5198e+008 % |
| Gross Profit (p.s.) | 3.42 |
| Sales Per Share | 5.64 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 39.6 |
| Price to Book value | 0 |
| Price to Sales | 15.42 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.384e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|